On the public citation graph

Vaccine R&D success rates and development times

https://doi.org/10.1038/nbt0596-591
0 signed · 69 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1007/978-1-4615-1823-5_3openalex-snapshot
Preclinical Safety Assessment Considerations in Vaccine Development
inferredcites →https://doi.org/10.1007/978-1-4615-1823-5_4openalex-snapshot
Regulatory Considerations in Vaccine Design
inferredcites →https://doi.org/10.1007/978-1-4615-1823-5_5openalex-snapshot
Clinical Considerations in Vaccine Trials with Special Reference to Candidate HIV Vaccines
inferredcites →https://doi.org/10.1007/978-1-4615-1823-5_6openalex-snapshot
Laboratory Empiricism, Clinical Design, and Social Value
inferredcites →https://doi.org/10.1007/bf01690995openalex-snapshot
Immunity to diphtheria in Northern Norway and Northwestern Russia
inferredcites →https://doi.org/10.1016/0140-6736(90)92266-kopenalex-snapshot
Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial
inferredcites →https://doi.org/10.1016/0140-6736(93)91069-xopenalex-snapshot
Risk of aseptic meningitis after measles, mumps,and rubella vaccine in UK children
inferredcites →https://doi.org/10.1016/0264-410x(95)00027-xopenalex-snapshot
Discussion
inferredcites →https://doi.org/10.1016/s0140-6736(81)90791-1openalex-snapshot
THE HORSE-RACING EFFECT
inferredcites →https://doi.org/10.1016/s0140-6736(88)90120-1openalex-snapshot
SAFETY, IMMUNOGENICITY, AND EFFICACY OF RECOMBINANT LIVE ORAL CHOLERA VACCINES, CVD 103 AND CVD 103-HgR
inferredcites →https://doi.org/10.1038/nbt0794-674openalex-snapshot
Biopharmaceutical R&D Success Rates and Development Times
inferredcites →https://doi.org/10.1093/infdis/168.6.1536openalex-snapshot
Safety and Immunogenicity of Live Oral Cholera Vaccine Candidate CVD 110, a ctxA ctxAzot zotace Derivative of El Tor Ogawa Vibrio cholerae
inferredcites →https://doi.org/10.1172/jci116141openalex-snapshot
Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A.

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.1099495openalex-extracted
R&D Models: Lessons from Vaccine History
inferred← citeshttps://doi.org/10.1002/3527600906.mcb.200400125openalex-snapshot
Vaccine Research and Development Methodology
inferred← citeshttps://doi.org/10.1002/9781118870914.ch14openalex-snapshot
Facility Design for Vaccine Manufacturing—Regulatory, Business, and Technical Considerations and a Risk‐Based Design Approach
inferred← citeshttps://doi.org/10.1002/9783527632909.ch15openalex-snapshot
Scientific, Technical, and Economic Aspects of Vaccine Research and Development
inferred← citeshttps://doi.org/10.1007/978-0-306-48536-7_28openalex-snapshot
Infectious Diseases in Asia
inferred← citeshttps://doi.org/10.1007/s11151-017-9579-7openalex-snapshot
Is “Delitigation” Associated with a Change in Product Safety? The Case of Vaccines
inferred← citeshttps://doi.org/10.1007/s12026-020-09154-4openalex-snapshot
Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development
inferred← citeshttps://doi.org/10.1007/s44217-025-00472-zopenalex-snapshot
Cards, cubes, and collaboration: a case study of the development of an educational board game
inferred← citeshttps://doi.org/10.1016/b978-0-12-369408-9.00004-4openalex-snapshot
Vaccine Development Pathway
inferred← citeshttps://doi.org/10.1016/b978-0-323-85941-7.00002-4openalex-snapshot
Controlled human infection modeling and vaccine development
inferred← citeshttps://doi.org/10.1016/j.intimp.2022.109175openalex-snapshot
Recent advances in the vaccine development for the prophylaxis of SARS Covid-19
inferred← citeshttps://doi.org/10.1016/j.tvjl.2008.02.023openalex-snapshot
Infectious diseases know no borders: A plea for more collaboration between researchers in human and veterinary vaccines
inferred← citeshttps://doi.org/10.1016/j.vaccine.2005.07.077openalex-snapshot
Human vaccine research and development: An overview
inferred← citeshttps://doi.org/10.1016/j.vaccine.2008.03.008openalex-snapshot
Development of a travelers’ diarrhea vaccine for the military: How much is an ounce of prevention really worth?
inferred← citeshttps://doi.org/10.1016/j.vaccine.2009.07.094openalex-snapshot
Development pathway for biodefense vaccines
inferred← citeshttps://doi.org/10.1016/j.vaccine.2011.06.051openalex-snapshot
The gold industry standard for risk and cost of drug and vaccine development revisited
inferred← citeshttps://doi.org/10.1016/j.vaccine.2012.09.071openalex-snapshot
Development of new generation influenza vaccines
inferred← citeshttps://doi.org/10.1016/j.vaccine.2012.12.032openalex-snapshot
Delivering the promise of the Decade of Vaccines: Opportunities and challenges in the development of high quality new vaccines
inferred← citeshttps://doi.org/10.1016/j.vaccine.2014.02.047openalex-snapshot
Vaccine R&D: Past performance is no guide to the future
inferred← citeshttps://doi.org/10.1016/j.vaccine.2018.09.002openalex-snapshot
Rapid quantification of vesicular stomatitis virus in Vero cells using Laser Force Cytology
inferred← citeshttps://doi.org/10.1016/j.vaccine.2018.11.050openalex-snapshot
A cost analysis of producing vaccines in developing countries
inferred← citeshttps://doi.org/10.1016/s0140-6736(21)00306-8openalex-snapshot
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment
inferred← citeshttps://doi.org/10.1016/s0169-409x(98)00010-6openalex-snapshot
Development and application of PROVAX™ adjuvant formulation for subunit cancer vaccines
inferred← citeshttps://doi.org/10.1016/s0169-4758(97)01060-0openalex-snapshot
Leishmania vaccines: Old and New
inferred← citeshttps://doi.org/10.1016/s2214-109x(18)30346-2openalex-snapshot
Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study
inferred← citeshttps://doi.org/10.1023/a:1025336903645openalex-snapshot
Setting Prices for New Vaccines (in Advance)
inferred← citeshttps://doi.org/10.1038/nrd2035openalex-snapshot
Applying the concepts of financial options to stimulate vaccine development
inferred← citeshttps://doi.org/10.1038/s41541-023-00646-6openalex-snapshot
Optimal global spending for group A Streptococcus vaccine research and development
inferred← citeshttps://doi.org/10.1038/s41578-022-00490-5openalex-snapshot
Machine learning for a sustainable energy future
inferred← citeshttps://doi.org/10.1073/pnas.2321978121openalex-snapshot
The economic case for scaling up health research and development: Lessons from the COVID-19 pandemic
inferred← citeshttps://doi.org/10.1089/bsp.2007.0030openalex-snapshot
Incentives for Biodefense Countermeasure Development
inferred← citeshttps://doi.org/10.1093/cid/ciaa935openalex-snapshot
Evaluating Use Cases for Human Challenge Trials in Accelerating SARS-CoV-2 Vaccine Development
inferred← citeshttps://doi.org/10.1126/science.1232910openalex-snapshot
Accelerating Next-Generation Vaccine Development for Global Disease Prevention
inferred← citeshttps://doi.org/10.1128/cmr.00005-06openalex-snapshot
Emerging Respiratory Viruses: Challenges and Vaccine Strategies
inferred← citeshttps://doi.org/10.1162/0033553041382166openalex-snapshot
Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry
inferred← citeshttps://doi.org/10.1186/s12916-023-02924-5openalex-snapshot
Reactogenicity and safety of COVID-19 primary immunisation and booster vaccination regimens: a comparative observational cohort study
inferred← citeshttps://doi.org/10.1371/journal.pntd.0001803openalex-snapshot
Analysis of Neglected Tropical Disease Drug and Vaccine Development Pipelines to Predict Issuance of FDA Priority Review Vouchers over the Next Decade
inferred← citeshttps://doi.org/10.1371/journal.pone.0057755openalex-snapshot
Risk in Vaccine Research and Development Quantified
inferred← citeshttps://doi.org/10.1377/hlthaff.25.4.1061openalex-snapshot
The Impact Of Globalization On Vaccine Development And Availability
inferred← citeshttps://doi.org/10.1586/14760584.2015.1074043openalex-snapshot
Rodents as pre-clinical models for predicting vaccine performance in humans
inferred← citeshttps://doi.org/10.1586/14760584.7.10.1457openalex-snapshot
Vaccines and global stability: achievements and challenges
inferred← citeshttps://doi.org/10.2105/ajph.2005.074583openalex-snapshot
Assembling a Global Vaccine Development Pipeline for Infectious Diseases in the Developing World
inferred← citeshttps://doi.org/10.2105/ajph.94.11.1931openalex-snapshot
Research and Development of New Vaccines Against Infectious Diseases
inferred← citeshttps://doi.org/10.23919/picmet.2019.8893968openalex-snapshot
The Productivity of Drug Development: A Systematic Review
inferred← citeshttps://doi.org/10.3386/w9460openalex-snapshot
Health Policy and Technological Change: Evidence from the Vaccine Industry
inferred← citeshttps://doi.org/10.3389/fimmu.2014.00241openalex-snapshot
Biomarkers of Safety and Immune Protection for Genetically Modified Live Attenuated Leishmania Vaccines Against Visceral Leishmaniasis – Discovery and Implications
inferred← citeshttps://doi.org/10.3389/fpubh.2021.612541openalex-snapshot
Barriers Influencing Vaccine Development Timelines, Identification, Causal Analysis, and Prioritization of Key Barriers by KOLs in General and Covid-19 Vaccine R&D
inferred← citeshttps://doi.org/10.3390/vaccines10101589openalex-snapshot
Rapid In-Process Measurement of Live Virus Vaccine Potency Using Laser Force Cytology: Paving the Way for Rapid Vaccine Development
inferred← citeshttps://doi.org/10.3390/vaccines9101129openalex-snapshot
Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle Vaccines
inferred← citeshttps://doi.org/10.4103/jnsm.jnsm_160_20openalex-snapshot
The COVID-19 Vaccines
inferred← citeshttps://doi.org/10.53913/aduveterinary.1662593openalex-snapshot
Advancing Vaccine Development: The Role of In Vitro Models and Progress in Reducing Animal Testing
inferred← citeshttps://doi.org/10.6084/m9.figshare.23550287openalex-snapshot
Additional file 1 of Reactogenicity and safety of COVID-19 primary immunisation and booster vaccination regimens: a comparative observational cohort study
inferred← citeshttps://doi.org/10.6084/m9.figshare.23550290openalex-snapshot
Additional file 2 of Reactogenicity and safety of COVID-19 primary immunisation and booster vaccination regimens: a comparative observational cohort study
inferred← citeshttps://doi.org/10.6084/m9.figshare.23550293openalex-snapshot
Additional file 3 of Reactogenicity and safety of COVID-19 primary immunisation and booster vaccination regimens: a comparative observational cohort study
inferred← citeshttps://doi.org/10.70675/6472d1ebz5bf2z4a0bza1cdz48b8a11e3648openalex-snapshot
Contre-mesures médicales contre les risques NRBC : quelles solutions pour un développement facilité dans une économie de marché ?
inferred← citeshttps://doi.org/10.7326/m20-5350openalex-snapshot
Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.